Do We Still Need Lead-in Dosing of Nevirapine in Hiv-Infected Patients Who Are Receiving Rifampicin-Containing Antituberculous Therapy?

醫學檢驗暨生物技術學系CHANG, SUI-YUANSUI-YUANCHANGLIN, SHU-WENSHU-WENLINHUNG, CHIEN-CHINGCHIEN-CHINGHUNG2010-06-292018-07-062010-06-292018-07-062009http://ntur.lib.ntu.edu.tw//handle/246246/186650en-USDo We Still Need Lead-in Dosing of Nevirapine in Hiv-Infected Patients Who Are Receiving Rifampicin-Containing Antituberculous Therapy?